What is Johnson & Johnson's innovative medicine — amortization?

Johnson & Johnson (JNJ) reported innovative medicine — amortization of $800M in Q1 2026.

How has Johnson & Johnson's innovative medicine — amortization changed year-over-year?

Johnson & Johnson's innovative medicine — amortization increased by 33.3% year-over-year, from $600M to $800M.

What does innovative medicine — amortization mean?

This represents the periodic expense recognized for the systematic allocation of the cost of finite-lived intangible assets, such as patents and acquired technology, within the Innovative Medicine segment. It reflects the non-cash consumption of intellectual property value over its useful life.

Johnson & Johnson JNJ Innovative Medicine — Amortization

Other segment segments

MEDTECH

$500M0.0%

Similar metrics at other companies

MEIMedical — Intangible Amortization

$0—

NOVTMedical Solutions — Intangible Amortization

$3.66M+16.2%

OPKPharmaceutical — Intangible Amortization

$16.43M+2.0%

APTVIntelligent Systems — Amortization

$22M0.0%

CPRXAmortization Expenses Of Intangible Asset

$9.7M+3.8%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Amortization of intangibles

$8.1M-1.9%

Other financials

Income statement

See full

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

See full

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

See full

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

See full

Market cap$623.71B+66.9%

Enterprise value$657.01B+61.9%

P/E29.6×+13.2×

P/S6.5×+2.3×

Profitability

See full

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

See full

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentForAmortization.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — amortization.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — amortization?: Johnson & Johnson (JNJ) reported innovative medicine — amortization of $800M in Q1 2026.
How has Johnson & Johnson's innovative medicine — amortization changed year-over-year?: Johnson & Johnson's innovative medicine — amortization increased by 33.3% year-over-year, from $600M to $800M.
What does innovative medicine — amortization mean?: This represents the periodic expense recognized for the systematic allocation of the cost of finite-lived intangible assets, such as patents and acquired technology, within the Innovative Medicine segment. It reflects the non-cash consumption of intellectual property value over its useful life.